ArticleThe pharmacogenomics journal2014
Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases.
Article in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.Pediatric rheumatology online journal · 2014Pooled it
- Glutathione S-Transferase Gene Polymorphisms as Predictors of Methotrexate Efficacy in Juvenile Idiopathic Arthritis.Biomedicines · 2024Article
- Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis.Rheumatology (Oxford, England) · 2024Article
- Characterization of Hepatitis B Virus Integrations Identified in Hepatocellular Carcinoma Genomes.Viruses · 2021Article
- Methotrexate Treatment of Newly Diagnosed RA Patients Is Associated With DNA Methylation Differences at Genes Relevant for Disease Pathogenesis and Pharmacological Action.Frontiers in immunology · 2021Observational
- Genomic risk scores for juvenile idiopathic arthritis and its subtypes.Annals of the rheumatic diseases · 2020Article
- The relationship of the immune response mediator genes’ polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritisTurkish journal of medical sciences · 2020Article
- Article
- Methotrexate an Old Drug with New Tricks.International journal of molecular sciences · 2019Review
- [New therapy approaches, better outcomes? : Results from inception cohorts for patients with juvenile idiopathic arthritis].Zeitschrift fur Rheumatologie · 2019Review
- ThePharmacogenomics · 2019Review
- Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.Eye (London, England) · 2019Article
- Association ofACR open rheumatology · 2019Article
- Early and Accurate Prediction of Clinical Response to Methotrexate Treatment in Juvenile Idiopathic Arthritis Using Machine Learning.Frontiers in pharmacology · 2019Article
- Identification of Target Genes at Juvenile Idiopathic Arthritis GWAS Loci in Human Neutrophils.Frontiers in genetics · 2019Article
- Immunomics in Pediatric Rheumatic Diseases.Frontiers in medicine · 2019Review
- Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.Pediatric rheumatology online journal · 2018Article
- Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients.The pharmacogenomics journal · 2018Review
- A multi-stage genome-wide association study of uterine fibroids in African Americans.Human genetics · 2017Article
- Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate.Rheumatology (Oxford, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 8 institutions in 4 countries.
Funding
Abstract
Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis (JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to identify non-responders: earlier identification could lead to a targeted treatment. We genotyped 759 JIA cases from the UK, the Netherlands and Czech Republic. Clinical variables were measured at baseline and 6 months after start of the treatment. In Phase I analysis, samples were analysed for the association with MTX response using ordinal regression of ACR-pedi categories and linear regression of change in clinical variables, and identified 31 genetic regions (P<0.001). Phase II analysis increased SNP density in the most strongly associated regions, identifying 14 regions (P<1 × 10(-5)): three contain genes of particular biological interest (ZMIZ1, TGIF1 and CFTR). These data suggest a role for novel pathways in MTX response and further investigations within associated regions will help to reach our goal of predicting response to MTX in JIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.